Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents that inhibit PH activity to stabilize HIF-α and promote the production of endogenous EPO, thereby enhancing the production of hemoglobin (Hb) and erythrocytes [8]. The gene discussed is EPO; the disease is anemia.